Dominari Financial, Inc. Signs Definitive Agreement to Purchase Broker-Dealer

Acquisition will accelerate growth strategy

NEW YORK, September 9, 2022 /PRNewswire/ — Dominari Financial, Inc., the financial services subsidiary of AIkido Pharma Inc., (NASDAQ: AIKI) has entered into an exclusive agreement to acquire a brokerage firm. This is Dominari’s first acquisition since its launch in June. Details of the proposed purchase can be found in the 8K filed with the SEC.

Dominari Financial was established with the intention of acquiring income-generating assets in the fintech and financial services industry. “Our goal has always been to move quickly to execute a strategy of rolling out wealth management companies that cater to ultra-high net worth investors. This transformative purchase not only accelerates our timeline, but also gives us the organizational infrastructure and necessary technology to make Dominari a financial services powerhouse,” said Carlos Aldavero, Dominari President.

Kyle Laine, a member of AIkido’s board of directors, acted as matchmaker on the deal and will continue to advise Mr. Aldavero on the purchase. “The Board of Directors fully supports the diversification strategy of which Dominari Financial is the centerpiece,” added Wool. “Once approved by FINRA, this acquisition will propel Dominari forward and lay the foundation for future acquisitions. I look forward to working closely with Carlos to continue to identify synergistic companies to add to the portfolio.” he continued.

Upon FINRA’s approval of the transaction, this acquisition will enable Dominari Financial to provide banking and lending services through a collaborative agreement with a third-party institution, providing the full balance sheet to UHNW investors, corporates and to institutional clients once the transaction has officially closed. .

Dominari Financial, Inc. Mission Statement:

Dominari is a dynamic, forward-thinking financial services company that creates wealth for all stakeholders by capitalizing on emerging trends in the financial services industry and identifying future opportunities at an early stage that will generate a rate of return high for investors.

About AIkido Pharma Inc.

AIkido Pharma Inc. was originally established in 1967 and is a biotechnology company with a diverse portfolio of small molecule anticancer and antiviral therapeutics. The Company’s platform consists of patented technology sourced from leading universities and researchers, and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with educational institutions. world-renowned, including the University of Texas in Austin and the University of Maryland at Baltimore. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer and prostate cancer. We are constantly looking to expand our pipeline to address unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that could potentially inhibit the replication of several viruses, including influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebola virus and Marburg virus.

Forward-looking statements

Certain statements contained in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may”, “could”, “will”, “should”, “believe”, “expect”, “anticipate”, “estimate”, “continue”, “predict”, “plan” , “project”, “” Although the Company believes that these forward-looking statements are reasonable, undue reliance should not be placed on these forward-looking statements, which are based on information available to us as of the date of this release. These forward-looking statements are based on current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company’s filings with the SEC, without limitation to risk associated with its activities contained therein. Therefore, actual results could differ materially. The Company expressly disclaims any obligation to update or change any statements, whether as a result of new information, future events or otherwise, except as required by law.

SOURCEDominari Financial, Inc.

About the author